Hemostemix Appoints the Honourable Sheila Copps, OC, PC, to Board of Advisors and Ratifies Thomas Smeenk as Chief Executive Officer

Calgary, Alberta–(Newsfile Corp. – April 7, 2020) – Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (“Hemostemix” or the “Company”) is pleased to announce the appointment of the Honorable Sheila Copps, OC, PC, to its Board of Advisors. Sheila was the Deputy Prime Minister of Canada, Minister of Environment, Minister of Heritage and a senior member of the federal cabinet for 10 years. From her work on diversity and inclusion, to protection of the environment, to support for young Canadians and women, Sheila has had a storied career that has left an indelible mark on Canadian public policy.

Among her achievements, Sheila brought forward what was the strongest federal environmental assessment legislation in the world; established Young Canada Works to provide annual summer employment for youth; brought in copyright protection for Canadian recording artists; and led ministers of culture from over 50 nations in the development of the first ever International Network on Cultural Diversity.

Sheila earned a Bachelor of Arts (Honors) in French and English from the University of Western Ontario in London and pursued further studies at McMaster University in Hamilton and the University of Rouen in France. In 1998, she received an Honorary Doctorate in Law from Université Sainte-Anne in Nova Scotia in recognition of her efforts to promote bilingualism and her commitment to advancing the French language and culture in Canada.

In recent years, Sheila has been working both in French and English as a journalist, broadcaster, and political commentator. She is the author of two books, Nobody’s Baby and Worth Fighting For.

“Sheila’s counsel of the board of directors and management based on her experience, track record of firsts, accomplishments and education are exactly what is needed as we build out a globally focused Canadian-based stem cell therapy company,” said Thomas Smeenk, President & CEO. “We are honored to welcome Sheila to our team!”

“I am absolutely delighted to be part of this initiative. With the widespread scourge of diabetes, Hemostemix could be a lifesaver,” added Sheila Copps.

The Company also announces the board of directors has ratified Thomas Smeenk as the Chief Executive Officer. Together with the late Roger Bergersen, Thomas was one of the original co-founders of the predecessor company to Hemostemix.

ABOUT HEMOSTEMIX INC.

Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

For more information, please visit www.hemostemix.com.
Contact: Thomas Smeenk, President, CEO & Founder
TSmeenk@Hemostemix.com
905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” and similar expressions, or that events or conditions “will,” “would,” “may,” “could,” or “should” occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. By their nature forward-looking statements are subject to known and unknown risks, uncertainties, and other factors which may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to fund operations and access the capital required to continue operations, the Company’s stage of development, the ability to complete its current CLI clinical trial, complete a futility analysis and the results of such, future clinical trials and results, long-term capital requirements and future developments in the Company’s markets and the markets in which it expects to compete, risks associated with its strategic alliances and the impact of entering new markets on the Company’s operations. Each factor should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise. Additional information identifying risks and uncertainties are contained in the Company’s filing with the Canadian securities regulators, which filings are available at www.sedar.com.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/54198